(BSX) Boston Scientific - Overview
Sector: Healthcare | Industry: Medical Devices | Exchange: NYSE (USA) | Market Cap: 79.327m USD | Total Return: -49.8% in 12m
Stents, Catheters, Pacemakers, Endoscopes, Neuromodulators
Total Rating 39
Safety 76
Buy Signal -0.75
Medical Devices
Industry Rotation: +6.2
Industry Rotation: +6.2
Market Cap:
79.3B
Avg Turnover: 1.05B
Avg Turnover: 1.05B
Risk 3d forecast
Volatility36.1%
VaR 5th Pctl5.75%
VaR vs Median-3.98%
Reward TTM
Sharpe Ratio-2.14
Rel. Str. IBD1.5
Rel. Str. Peer Group4.5
Character TTM
Beta0.556
Beta Downside0.662
Hurst Exponent0.471
Drawdowns 3y
Max DD51.29%
CAGR/Max DD-0.01
CAGR/Mean DD-0.09
EPS (Earnings per Share)
EPS CAGR: 17.28%
EPS Trend: 98.3%
EPS Trend: 98.3%
Last SUE: 0.40
Qual. Beats: 0
Qual. Beats: 0
Revenue
Rev. CAGR: 13.43%
Rev. Trend: 98.7%
Rev. Trend: 98.7%
Last SUE: 0.53
Qual. Beats: 0
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Description: BSX Boston Scientific
Boston Scientific Corporation is a global medical technology manufacturer headquartered in Marlborough, Massachusetts, specializing in minimally invasive medical devices. The company operates through two primary segments: MedSurg and Cardiovascular. Its product portfolio addresses a wide range of clinical areas, including gastrointestinal endoscopy, urology, neuromodulation, and cardiac rhythm management.
The company maintains a focus on high-growth categories such as Left Atrial Appendage Closure (LAAC) and single-use endoscopes. As a member of the Health Care Equipment sub-industry, Boston Scientific operates within a sector characterized by high research and development requirements and rigorous regulatory approval cycles. Its business model relies on a combination of recurring revenue from single-use consumables and capital equipment sales to hospitals and specialized clinics.
Analyzing the historical valuation trends on ValueRay can provide further context on the company’s market positioning.
- Electrophysiology market share gains driven by Farapulse pulsed field ablation system
- WATCHMAN FLX device adoption expands left atrial appendage closure revenue
- Cardiovascular and MedSurg segment growth sustains double-digit organic revenue expansion
- Strategic acquisitions and R&D investment accelerate entry into high-growth medtech categories
- Regulatory approvals and clinical trial data influence long-term valuation multiples
Piotroski VR‑10 (Strict)
6.5
| Net Income: 3.55b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 0.60 > 1.0 |
| NWC/Revenue: 19.95% < 20% (prev 12.97%; Δ 6.98% < -1%) |
| CFO/TA 0.10 > 3% & CFO 4.34b > Net Income 3.55b |
| Net Debt (9.51b) to EBITDA (4.76b): 2.00 < 3 |
| Current Ratio: 1.90 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.50b) vs 12m ago 0.13% < -2% |
| Gross Margin: 70.42% > 18% (prev 0.62%; Δ 6.98k% > 0.5%) |
| Asset Turnover: 48.80% > 50% (prev 43.73%; Δ 5.07% > 0%) |
| Interest Coverage Ratio: 5.76 > 6 (EBITDA TTM 4.76b / Interest Expense TTM 357.0m) |
Altman Z''
1.82
| A: 0.09 (Total Current Assets 8.68b - Total Current Liabilities 4.57b) / Total Assets 44.35b |
| B: 0.16 (Retained Earnings 6.91b / Total Assets 44.35b) |
| C: 0.05 (EBIT TTM 2.06b / Avg Total Assets 42.25b) |
| D: 0.36 (Book Value of Equity 6.53b / Total Liabilities 18.25b) |
| Altman-Z'' Score: 1.82 = BBB |
Beneish M
-3.08
| DSRI: 0.96 (Receivables 3.03b/2.69b, Revenue 20.61b/17.55b) |
| GMI: 0.88 (GM 70.42% / 61.84%) |
| AQI: 0.97 (AQ_t 0.70 / AQ_t-1 0.72) |
| SGI: 1.17 (Revenue 20.61b / 17.55b) |
| TATA: -0.02 (NI 3.55b - CFO 4.34b) / TA 44.35b) |
| Beneish M-Score: -3.08 (Cap -4..+1) = AA |
What is the price of BSX shares?
As of May 17, 2026, the stock is trading at USD 52.68 with a total of 14,802,213 shares traded.
Over the past week, the price has changed by -2.32%, over one month by -18.46%, over three months by -30.95% and over the past year by -49.76%.
Over the past week, the price has changed by -2.32%, over one month by -18.46%, over three months by -30.95% and over the past year by -49.76%.
Is BSX a buy, sell or hold?
Boston Scientific has received a consensus analysts rating of 4.59.
Therefore, it is recommended to buy BSX.
- StrongBuy: 23
- Buy: 8
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BSX price?
| Analysts Target Price | 85.2 | 61.7% |
Boston Scientific (BSX) - Fundamental Data Overview
as of 14 May 2026
P/E Trailing = 22.3305 P/E Forward = 16.0
P/S = 3.8482
P/B = 3.0993
P/EG = 0.6519
Revenue TTM = 20.61b USD
EBIT TTM = 2.06b USD
EBITDA TTM = 4.76b USD
Long Term Debt = 10.86b USD (from longTermDebt, last quarter)
Short Term Debt = 41.0m USD (from shortTermDebt, last quarter)
Debt = 11.03b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 9.51b USD (from netDebt column, last quarter)
Enterprise Value = 88.83b USD (79.33b + Debt 11.03b - CCE 1.52b)
Interest Coverage Ratio = 5.76 (Ebit TTM 2.06b / Interest Expense TTM 357.0m)
EV/FCF = 25.81x (Enterprise Value 88.83b / FCF TTM 3.44b)
FCF Yield = 3.87% (FCF TTM 3.44b / Enterprise Value 88.83b)
FCF Margin = 16.70% (FCF TTM 3.44b / Revenue TTM 20.61b)
Net Margin = 17.24% (Net Income TTM 3.55b / Revenue TTM 20.61b)
Gross Margin = 70.42% ((Revenue TTM 20.61b - Cost of Revenue TTM 6.10b) / Revenue TTM)
Gross Margin QoQ = 69.44% (prev 74.50%)
Tobins Q-Ratio = 2.00 (Enterprise Value 88.83b / Total Assets 44.35b)
Interest Expense / Debt = 0.82% (Interest Expense 90.0m / Debt 11.03b)
Taxrate = 14.56% (493.0m / 3.38b)
NOPAT = 1.76b (EBIT 2.06b * (1 - 14.56%))
Current Ratio = 1.90 (Total Current Assets 8.68b / Total Current Liabilities 4.57b)
Debt / Equity = 0.43 (Debt 11.03b / totalStockholderEquity, last quarter 25.86b)
Debt / EBITDA = 2.00 (Net Debt 9.51b / EBITDA 4.76b)
Debt / FCF = 2.76 (Net Debt 9.51b / FCF TTM 3.44b)
Total Stockholder Equity = 23.98b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.41% (Net Income 3.55b / Total Assets 44.35b)
RoE = 14.82% (Net Income TTM 3.55b / Total Stockholder Equity 23.98b)
RoCE = 5.90% (EBIT 2.06b / Capital Employed (Equity 23.98b + L.T.Debt 10.86b))
RoIC = 4.98% (NOPAT 1.76b / Invested Capital 35.27b)
WACC = 7.06% (E(79.33b)/V(90.36b) * Re(7.94%) + D(11.03b)/V(90.36b) * Rd(0.82%) * (1-Tc(0.15)))
Discount Rate = 7.94% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 0.54%
[DCF] Terminal Value 84.74% ; FCFF base≈3.21b ; Y1≈3.97b ; Y5≈6.77b
[DCF] Fair Price = 90.61 (EV 144.18b - Net Debt 9.51b = Equity 134.67b / Shares 1.49b; r=7.06% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 98.27 | EPS CAGR: 17.28% | SUE: 0.40 | # QB: 0
Revenue Correlation: 98.70 | Revenue CAGR: 13.43% | SUE: 0.53 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.83 | Chg30d=-3.75% | Revisions=-84% | Analysts=25
EPS next Quarter (2026-09-30): EPS=0.85 | Chg30d=-2.72% | Revisions=-83% | Analysts=24
EPS current Year (2026-12-31): EPS=3.38 | Chg30d=-2.36% | Revisions=-88% | GrowthEPS=+10.4% | GrowthRev=+8.0%
EPS next Year (2027-12-31): EPS=3.76 | Chg30d=-3.51% | Revisions=-88% | GrowthEPS=+11.4% | GrowthRev=+8.9%
[Analyst] Revisions Ratio: -88%